Memo Therapeutics AG. (2/1/19). "Press Release: Memo Therapeutics Announces the Development of a Droplet Sorter Enabling Functional Antibody Screening in a High-Throughput Format".

	Organisation	Memo Therapeutics AG
	Product	drug screening (technology)
	Product 2	MemoMAB™ antibody discovery platform
	Person	Esslinger, Christoph (Memo Therapeutics AG 201805 CEO)
	Person 2	Fischer, Karsten (Memo Therapeutics 201806– CEO before BioMedPartners + WestLB)

This novel microfluidic droplet sorter will be deployed downstream of the MemoMAB antibody repertoire biobanking platform to enable functional screening in high througput format with a series of functional assays such as:

Cell-binding
Virus-neutralization
Identification of agonistic/antagonistic antibodies
ADCC assays

“This is a major step in the technology development at Memo since we are now able to directly screen antibody repertoire libraries from rare patients or immunized animals for antibodies with the desired functional activity in a single day. “ says Dr. Christoph Esslinger, CSO.

Dr. Karsten Fischer, CEO, comments: “Having such a tool at hand will enable us to pick the optimal antibody development candidates out of diverse repertoires for our own pipeline and attract high-profile partnerships with pharmaceutical companies.”

On the coprorate side, Memo has followed the planned trajectory and has moved its premises to State-of-the-art laboratories at Schlieren and launched a new corporate design including a new web site that can be visited at: http://www.memo-therapeutics.com

About Memo

Memo Therapeutics AG is an innovator in the field of antibody discovery and immune repertoire analysis. Exploiting the power of our microfluidic single-cell molecular cloning and screening technologies we engage in antibody discovery across species and indications for proprietary and partnered projects. Our current pipeline features programmes in infectious diseases and immuno-oncology.

Record changed: 2019-02-15